Michelle Morrow

Michelle Morrow is an accomplished scientific leader with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Scientific Officer at Avacta since October 2024, Michelle previously held the position of SVP, Head of invoX Therapeutic Innovation at invoX Pharma, where a new discovery and preclinical research department was established following the transition of a team from F-star Therapeutics. With a strong background at F-star, Michelle progressed through various roles, including SVP, Head of Research, and VP, Preclinical Translational Pharmacology, contributing significantly to multiple clinical programs and the company’s transition to public listing. Prior experience includes a scientific leadership role at MedImmune, where impactful work was done on immuno-oncology programs, and a postdoctoral research position at UCL. Michelle holds a Ph.D. in Immunology from the University of Cambridge and a Bachelor’s Degree in Molecular Biology from Newcastle University.